<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tesamorelin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08869</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (<span class="caps">GHRH</span>) indicated for the reduction of excess abdominal fat in <span class="caps">HIV</span>-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for <span class="caps">HIV</span> infection.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>221</sub>H<sub>366</sub>N<sub>72</sub>O<sub>67</sub>S &#8226; xC<sub>2</sub>H<sub>4</sub>O<sub>2</sub> where x averages <sub>7</sub>.<sub>4</sub>  acetate counter ions per peptide molecule.</td></tr><tr><th>Protein average weight</th><td>5135.9 Daltons (base free)</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;results for sequence "Egrifta Sequence" starting "TyrAlaAspAla"
YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB08869/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Egrifta</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-(trans-3-Hexenoyl)-Human Growth Hormone Releasing Factor (1-44) Acetate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tesamorelin Acetate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Egrifta</td><td>Theratechnologies Inc. </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>901758-09-6</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. </td></tr><tr><th>Pharmacodynamics</th><td>Tesamorelin stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels.</td></tr><tr><th>Mechanism of action</th><td>By acting on the pituitary cells in the brain, tesamorelin stimulates production and release of the endogenous hormone (hGRF). Tesamorelin therapy predisposes the patient to glucose intolerance and can also increase the risk of type 2 diabetes, so the drug is contraindicated in pregnancy. </td></tr><tr><th>Absorption</th><td>The absolute bioavailability was determined to be less than 4% in healthy adult subjects following a 2 mg subcutaneous dose.</td></tr><tr><th>Volume of distribution</th><td><p>9.4&#177;3.1 L/kg in healthy subjects.<br>
10.5&#177;6.1 L/kg in <span class="caps">HIV</span>-infected patients.</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>No formal metabolism studies have been performed in humans.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>26 and 38 minutes in healthy subjects and HIV-infected patients, respectively.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Diarrhea, congestive heart failure, peripheral neuropathy, and loss of 
mobility were the four serious adverse events reported during 
the clinical studies</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, lyophilized, for solution</td><td>Subcutaneous</td><td>2 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5861379</td><td>2011-11-29</td><td>2015-05-26</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>isoelectric point</td><td>10.54</td><td>http://www.phosphosite.org/proteinAction.do?id=19016&amp;showAllSites=true</td></tr></table></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Spooner LM, Olin JL: Tesamorelin: a growth hormone-releasing factor analogue for <span class="caps">HIV</span>-associated lipodystrophy. Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22298602">Pubmed</a></li>
	<li>McLarnon A: Neuroendocrinology: Tesamorelin can improve cognitive function. Nat Rev Endocrinol. 2012 Oct;8(10):568. doi: 10.1038/nrendo.2012.151. Epub 2012 Aug 28. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22926095">Pubmed</a></li>
	<li>Bedimo R: Growth hormone and tesamorelin in the management of <span class="caps">HIV</span>-associated lipodystrophy. <span class="caps">HIV</span> <span class="caps">AIDS</span> (Auckl). 2011;3:69-79. doi: 10.2147/<span class="caps">HIV</span>.S14561. Epub 2011 Jul 10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22096409">Pubmed</a></li>
	<li>Dhillon S: Spotlight on tesamorelin in <span class="caps">HIV</span>-associated lipodystrophy. BioDrugs. 2011 Dec 1;25(6):405-8. doi: 10.2165/11208290-000000000-00000. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22050344">Pubmed</a></li>
	<li>Garg A: Acquired and inherited lipodystrophies. N Engl J Med. 2004 Mar 18;350(12):1220-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15028826">Pubmed</a></li>
	<li>Patel A, Gandhi H, Upaganlawar A: Tesamorelin: A hope for <span class="caps">ART</span>-induced lipodystrophy. J Pharm Bioallied Sci. 2011 Apr;3(2):319-20. doi: 10.4103/0975-7406.80763. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21687371">Pubmed</a></li>
	<li>Campbell RM, Lee Y, Rivier J, Heimer EP, Felix AM, Mowles TF: <span class="caps">GRF</span> analogs and fragments: correlation between receptor binding, activity and structure. Peptides. 1991 May-Jun;12(3):569-74. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1656403">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P01286" target="_blank">P01286 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/egrifta-drug.htm" target="_blank">http://www.rxlist.com/egrifta-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/egrifta.html" target="_blank">http://www.drugs.com/egrifta.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdr.net/drug-summary/egrifta?druglabelid=1374" target="_blank">http://www.pdr.net/drug-summary/egrifta?druglabelid=1374 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Tesamorelin" target="_blank">Tesamorelin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>H01AC06<ul class="atc-drug-tree"><li><a href="/atc/H#H">H &#8212; SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</a></li><li><a href="/atc/H01#H01">H01 &#8212; PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</a></li><li><a href="/atc/H01A#H01A">H01A &#8212; ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</a></li><li><a href="/atc/H01AC#H01AC">H01AC &#8212; Somatropin and somatropin agonists</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08869.pdf?1367369292">show</a>(1.53 MB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB08869.pdf?1367523381">show</a>(568 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>